Jamie L Todd1, Megan L Neely2, C A Finlen Copeland3, Courtney W Frankel4, John M Reynolds4, Scott M Palmer3. 1. Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine; Duke Clinical Research Institute. Electronic address: jamie.todd@dm.duke.edu. 2. Duke Clinical Research Institute; Department of Biostatistics and Bioinformatics Duke University Medical Center, Durham, North Carolina, USA. 3. Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine; Duke Clinical Research Institute. 4. Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine.
Abstract
BACKGROUND: Chronic lung allograft dysfunction (CLAD), including the phenotypes of bronchiolitis obliterans syndrome (BOS) and restrictive CLAD (R-CLAD), represents the leading cause of late death after lung transplantation. Little is known, however, regarding the natural history or prognostic significance of pulmonary function changes after the onset of these conditions. We examined changes in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) over the first 18 months after CLAD. We also sought to determine whether lung function changes occurring early after CLAD impact longer term outcomes. METHODS: We performed a retrospective analysis of 216 bilateral lung recipients with CLAD, which included those with R-CLAD (n = 65) or BOS (n = 151). The course of FEV1 and FVC after CLAD was described. Cox proportional hazards models were used to evaluate the impact of a ≥10% decline in FEV1 or FVC within the first 6 months of CLAD on graft loss after that time. RESULTS: Lung recipients with CLAD, whether BOS or R-CLAD, had the largest decreases in FEV1 and FVC within the first 6 months after onset. Moreover, a decline in FEV1 or FVC of ≥10% within the first 6 months after CLAD was associated with a significantly increased hazard for graft loss after that time (hazard ratio [HR] = 3.17, 95% confidence interval [CI] 1.56 to 6.42, p = 0.001, and HR = 2.80, 95% CI 1.66 to 4.70, p ≤ 0.001, respectively), an effect observed in both BOS and R-CLAD patients. CONCLUSIONS: Early physiologic changes after CLAD were independently associated with graft loss. This suggests lung function changes after CLAD, specifically a ≥10% decline in FEV1 or FVC, could be a surrogate measure of graft survival.
BACKGROUND:Chronic lung allograft dysfunction (CLAD), including the phenotypes of bronchiolitis obliterans syndrome (BOS) and restrictive CLAD (R-CLAD), represents the leading cause of late death after lung transplantation. Little is known, however, regarding the natural history or prognostic significance of pulmonary function changes after the onset of these conditions. We examined changes in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) over the first 18 months after CLAD. We also sought to determine whether lung function changes occurring early after CLAD impact longer term outcomes. METHODS: We performed a retrospective analysis of 216 bilateral lung recipients with CLAD, which included those with R-CLAD (n = 65) or BOS (n = 151). The course of FEV1 and FVC after CLAD was described. Cox proportional hazards models were used to evaluate the impact of a ≥10% decline in FEV1 or FVC within the first 6 months of CLAD on graft loss after that time. RESULTS: Lung recipients with CLAD, whether BOS or R-CLAD, had the largest decreases in FEV1 and FVC within the first 6 months after onset. Moreover, a decline in FEV1 or FVC of ≥10% within the first 6 months after CLAD was associated with a significantly increased hazard for graft loss after that time (hazard ratio [HR] = 3.17, 95% confidence interval [CI] 1.56 to 6.42, p = 0.001, and HR = 2.80, 95% CI 1.66 to 4.70, p ≤ 0.001, respectively), an effect observed in both BOS and R-CLADpatients. CONCLUSIONS: Early physiologic changes after CLAD were independently associated with graft loss. This suggests lung function changes after CLAD, specifically a ≥10% decline in FEV1 or FVC, could be a surrogate measure of graft survival.
Authors: Marc Estenne; Janet R Maurer; Annette Boehler; James J Egan; Adaani Frost; Marshall Hertz; George B Mallory; Gregory I Snell; Samuel Yousem Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: Harold R Collard; Talmadge E King; Becki Bucher Bartelson; Jason S Vourlekis; Marvin I Schwarz; Kevin K Brown Journal: Am J Respir Crit Care Med Date: 2003-05-28 Impact factor: 21.405
Authors: C Ashley Finlen Copeland; Laurie D Snyder; David W Zaas; W Jackson Turbyfill; W Austin Davis; Scott M Palmer Journal: Am J Respir Crit Care Med Date: 2010-05-27 Impact factor: 21.405
Authors: Stijn E Verleden; Pim A de Jong; David Ruttens; Elly Vandermeulen; Dirk E van Raemdonck; Johny Verschakelen; Bart M Vanaudenaerde; Geert M Verleden; Robin Vos Journal: J Heart Lung Transplant Date: 2013-12-17 Impact factor: 10.247
Authors: Elizabeth A Belloli; Xin Wang; Susan Murray; Ginia Forrester; Adrian Weyhing; Jules Lin; Tammy Ojo; Vibha N Lama Journal: Am J Respir Crit Care Med Date: 2015-07-15 Impact factor: 21.405
Authors: Kevin R Flaherty; Jeanette A Mumford; Susan Murray; Ella A Kazerooni; Barry H Gross; Thomas V Colby; William D Travis; Andrew Flint; Galen B Toews; Joseph P Lynch; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2003-05-28 Impact factor: 21.405
Authors: Geert M Verleden; Ganesh Raghu; Keith C Meyer; Allan R Glanville; Paul Corris Journal: J Heart Lung Transplant Date: 2013-10-24 Impact factor: 10.247
Authors: Vibha N Lama; Susan Murray; Robert J Lonigro; Galen B Toews; Andrew Chang; Christine Lau; Andrew Flint; Kevin M Chan; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2007-03-08 Impact factor: 21.405
Authors: Chen Yang Kevin Zhang; Musawir Ahmed; Ella Huszti; Liran Levy; Sarah E Hunter; Kristen M Boonstra; Sajad Moshkelgosha; Andrew T Sage; Sassan Azad; Ricardo Zamel; Rasheed Ghany; Jonathan C Yeung; Oscar M Crespin; Courtney Frankel; Marie Budev; Pali Shah; John M Reynolds; Laurie D Snyder; John A Belperio; Lianne G Singer; S Samuel Weigt; Jamie L Todd; Scott M Palmer; Shaf Keshavjee; Tereza Martinu Journal: J Heart Lung Transplant Date: 2020-05-19 Impact factor: 10.247